autologous CD20-4SCAR-expressing T cells 4SCAR20
Term · Oncology and biomedicine · MLC-T-ONC-011547
A preparation of genetically modified autologous T cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD20 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD20-4SCAR-expressing T cells 4SCAR20 are directed to and induce selective toxicity in CD20-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T cells and enhances safety of this agent. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T cells and antitumor activity.
| Identifier | MLC-T-ONC-011547 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-CD20 CAR-T cells 4SCAR20; 4S-CD20-CAR-T cell; CD20-specific 4th generation chimeric antigen receptor-modified T cells; CD20-4SCAR-expressing T lymphocytes; 4SCAR20 T cells; anti-CD20-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR20; CD20-scFv/CD28/CD137/CD27/CD3z-iCasp9 T cells |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011547",
"term": "autologous CD20-4SCAR-expressing T cells 4SCAR20",
"field": "Oncology and biomedicine",
"definition": "A preparation of genetically modified autologous T cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD20 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD20-4SCAR-expressing T cells 4SCAR20 are directed to and induce selective toxicity in CD20-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T cells and enhances safety of this agent. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T cells and antitumor activity.",
"synonyms": [
"anti-CD20 CAR-T cells 4SCAR20",
"4S-CD20-CAR-T cell",
"CD20-specific 4th generation chimeric antigen receptor-modified T cells",
"CD20-4SCAR-expressing T lymphocytes",
"4SCAR20 T cells",
"anti-CD20-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR20",
"CD20-scFv/CD28/CD137/CD27/CD3z-iCasp9 T cells"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autologous-cd20-4scar-expressing-t-cells-4scar20/"
}
Record 2,881 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.